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Abstract 
Objective: Investigation of variations in provider performance and its determinants may 
help inform strategies for improving patient outcomes.  
Methods: We used the National Heart Failure Audit comprising 68,772 patients with 
heart failure with reduced left ventricular ejection fraction (HFREF), admitted to 185 
hospitals in England and Wales (2007-2013). We investigated hospital adherence to three 
recommended key performance measures (KPM) for in-hospital care (ACE-inhibitors or 
ARBs on discharge, beta-blockers on discharge, and referral to specialist follow-up) 
individually and as a composite performance score. Hierarchical regression models were 
used to investigate hospital-level variation.  
Results: Hospital-level variation in adherence to composite KPM ranged from 50% to 
97% (median 79%), but after adjustments for patient characteristics and year of 
admission, only 8% (CI 7 % to 10%) of this variation was attributable to variations in 
hospital features. Similarly, hospital prescription rates for ACE-I/ARB and beta-blocker 
showed low adjusted hospital-attributable variations (7% CI 6% to 9% and 6% CI 5% to 
8%, for ACE-I/ARB and beta-blocker, respectively). Referral to specialist follow-up, 
however, showed larger variations (median 81%; range; 20%, 100%,) with 26% of this 
being attributable to hospital-level differences (CI 22% to 31%).  
Conclusions:  Only a small proportion of hospital variation in medication prescription 
after discharge was attributable to hospital-level features. This suggests that differences 
in hospital practices are not a major determinant of observed variations in prescription of 
investigated medications and outcomes. Future healthcare delivery efforts should 
consider evaluation and improvement of more ambitious KPM.  
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What is already known about this subject? 
 
Quality of care and outcomes for individuals suffering from heart failure are 
unsatisfactory in many regions of the world. Previous studies have reported wide 
variations in management of patients with heart failure across different healthcare 
systems. 
What does this study add? 
 
Only 8% of the total variation in the composite performance measure was due to 
differences in known and unknown hospital features. However, variation in referral for 
specialist follow-up was substantial and 26% of it was due to hospital-level features.  
 
How might this impact on clinical practice? 
 
Whilst further investment into costly organisational changes for management of HFREF in 
hospitals in England and Wales may still be useful for changing other important 
healthcare outcomes across hospitals, our study shows that such investments cannot be 
expected to lead to large reductions in variability in hospital adherence to heart failure 
performance measures examined in this study. Future healthcare delivery efforts should 
consider evaluation and improvement of more ambitious KPM.
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Introduction 
Over the last few years, substantial effort has been made to ensure that patients with 
heart failure and reduced left ventricular ejection fraction (HFREF) receive guideline-
recommended care that is known to improve outcomes. In many healthcare systems, 
professional societies and government agencies have formulated and endorsed quality 
standards for better implementation of recommended care.1–3 Despite these efforts, the 
quality of care and outcomes for individuals suffering from heart failure are 
unsatisfactory in many regions of the world.4,5  
 
Investigation of variations in adherence to recommended care among providers can 
inform decision-makers about the nature and drivers of deficiencies in quality of care, and 
whether these might be amenable to organisational changes.6 Given that such changes 
often require substantial financial and human resource investment, it is prudent to 
explore the extent to which differences in care practices are responsible for variation in 
quality of care and to estimate the impact of any proposed changes to service delivery.7,8  
 
We set out to measure the amount of variation among hospitals in their adherence to key 
performance measures (KPM) for management of patients with heart failure with HFREF 
and the extent to which this can be explained by hospital-level factors. 
Methods 
This study is a part of the UNVEIL-CHF study (Understanding National Variation and 
Effects of Interventions at different Levels of Care for Heart Failure), which aims to 
characterize variation in hospital care and outcomes for patients with heart failure.  
 
Page 5 of 26 
 
Data sources 
We used the National Heart Failure Audit for our primary analyses. The audit enrolls 
patients hospitalised with a primary diagnosis of heart failure in England and Wales.9 
Initially, in 2007, participating hospitals were asked to provide data on at least the first 10 
patients with a primary death or discharge diagnosis of heart failure in each month; this 
requirement has steadily increased and, from 2012, all hospitals in England and Wales 
were expected to report all unscheduled admissions due to heart failure to the audit. The 
dataset captures information about patient demographics, clinical characteristics, and 
follow-up information. The audit was supplemented by a survey of 185 English and Welsh 
hospitals, included in the National Heart Failure Audit, that provide care for patients with 
acute heart failure, capturing information on hospital characteristics, including human 
resources (e.g. number of cardiologists), referral pathways (e.g. heart transplantation) 
and other organisational features.  
Study population and outcomes 
Only hospital admissions in which the patient survived to discharge were eligible for 
inclusion in the study because collection of treatment variables was not mandated for 
patients who died in hospital. We restricted our analysis to patients with HFREF, 
diagnosed using echocardiogram, because clearly defined and evidence-based treatment 
recommendations exist only for this subgroup. Contra-indications to ACE-I/ARB and beta-
blockers were recorded and patients with any contra-indications were classified as 
missing for these variables. For patients with more than one reported hospital admission 
(10,280, 14.4%), we randomly selected one admission.  
 
 
Page 6 of 26 
 
The primary analyses of variation among hospitals in their adherence to key performance 
measures used patient-level outcomes for three key performance measures for HFREF: 
provision of an ACE-I/ARB, provision of a beta-blocker and referral for follow-up with a 
heart failure specialist (either referral for follow up with a cardiologist or with a heart 
failure specialist nurse), and their composite performance score (described below). We 
chose these KPMs as they were recommended by the American Heart Association’s Task 
Force on Performance Measures in 2012 and the UK National Institute for Health and 
Care Excellence (NICE) in 2014.3,10  
 
To generate the composite performance score, a mean of the provision of an ACE-I/ARB, 
provision of a beta-blocker and specialist follow-up was generated for each patient. This 
was averaged at the hospital level across all patients to generate a hospital level 
composite performance score (continuous score, ranging from 0 to 1, or 0% to 100%).11 
We chose to use process outcomes as our primary endpoint, rather than mortality, 
because the process outcomes selected represent established clinical standards and such 
outcomes are better suited than mortality or metrics with limited evidence-base for 
comparing performances between hospitals.12 
 
In a secondary analyses, we investigated variation among hospitals for risk-adjusted 
death at 30 days and at one-year after discharge (adjusted for age, sex, NYHA class [I, II, III 
or IV], peripheral oedema [none, mild, moderate or severe], history of diabetes, history of 
ischemic heart disease, history of hypertension, history of valve disease, atrial fibrillation, 
left bundle block, previous myocardial infarction, concomitant diastolic dysfunction, left 
ventricular hypertrophy and valve disease).  
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Statistical analysis 
We used multiple imputation using chained equations to impute missing covariates; five 
imputation sets were generated. No covariate was missing at a rate that exceeded 15%. 
Although multiple imputation relies upon the missing at random assumption (that is, that 
missing covariates and outcomes are missing at random conditional on other covariates), 
simulation studies have suggested that multiple imputation provides equivalent or better 
coverage and bias than complete case analysis, even when missingness is not at 
random.13,14 We therefore used multiple imputation rather than a complete case analysis.  
 
Continuous data were summarised using the mean and standard deviation or median and 
interquartile interval while categorical data were summarised using percentages. 
Hierarchical Poisson and normal regression models were used to examine time trends in 
the individual components of the composite score and the patient level composite score, 
respectively, with yearly rates modeled through the inclusion of calendar year as a 
categorical covariate. As the patient level composite score was not symmetric (2.3% of 
participants received a score of 0 while 58.1% received a score of 1), normal 
approximation condition for the patient level composite score was verified by 
bootstrapping. We conducted bootstrapping using 10000 replications and examined the 
distribution of the mean ICC. The mean ICC followed a normal distribution and the 
bootstrapped confidence intervals were identical to those derived using a normal 
approximation. 
 
Time trends in risk-adjusted 30-day mortality and one-year mortality were similarly 
examined through hierarchical Poisson models adjusted for patient case-mix (clinical 
characteristics listed below). These models were then used to predict 30-day and one-
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year risk-adjusted mortality for each year at the means of patient covariates. Statistical 
significance of changes in rates was determined by including year as a continuous 
covariate. 
 
To examine associations between hospital characteristics and their composite 
performance score, we divided hospitals into fifths based on their respective composite 
performance score (with the bottom fifth containing hospitals with the lowest composite 
score and the top fifth containing hospitals with the highest composite score). Hospital 
characteristics by fifth of composite performance score were summarized using 
proportions for categorical data and means for continuous variables. To examine whether 
hospital characteristics differed across fifths, continuous and categorical covariates at the 
hospital level were tested for trend using linear regression with hospital fifths as a 
continuous outcome. To further determine which hospital characteristics were associated 
with a better performance score, backwards stepwise regression was performed with the 
inclusion of all hospital characteristics and a p-value for exit of 0.01.  
 
In our main analysis, to investigate the degree to which patient case-mix, year of 
investigation and hospital features accounted for the variation in hospital performances, 
we used hierarchical logistic regression models. We first fitted an unconditional (null) 
model with only a hospital random intercept to quantify the amount of between-hospital 
variation. In the second model, we added 24 patient characteristics: demographic 
characteristics (age, sex); clinical characteristics (NYHA class [I, II, III or IV], peripheral 
oedema [none, mild, moderate or severe], history of diabetes, history of ischemic heart 
disease, history of hypertension, history of valve disease, atrial fibrillation, left bundle 
block, previous myocardial infarction, diastolic dysfunction, left ventricular hypertrophy 
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and valve disease) and dummy variables for year of admission (2007, 2008, 2009, 2010, 
2011, 2012, 2013) to investigate the extent to which differences in performance between 
hospitals was accounted for by patient case-mix and year of admission. In the third model, 
we added hospital characteristics independently associated with the composite 
performance score to determine whether the variation among hospitals could be 
accounted for by known hospital characteristics: tertiary hospital, number of full time 
equivalent consultant cardiologists, a multidisciplinary team with a cardiologist, a 
multidisciplinary team with a consultant with an interest in heart failure, a 
multidisciplinary team with a pharmacist, a multidisciplinary team with a psychologist, a 
multidisciplinary team with a social workers, coronary angiography capabilities, cardiac 
MRI capabilities, an outpatient service with a cardiologist and an outpatient service with a 
heart failure specialist nurse.  We used the intraclass correlation coefficient (ICC) to 
estimate the proportion of variance in performance that was attributable to the between-
hospital variation. We calculated the ICC from these hierarchical logistic models using the 
following equation: ICC=se^2/(se^2 + (π^2)/3), where se is the standard error of the 
random hospital intercept.15 This was supported by the median odds ratio (MOR), which 
reports between-hospital variation that is not explained by patient characteristics. The 
MOR works on the principle that, if two patients with ‘identical patient-level 
characteristics’, from two randomly selected hospitals are compared, any odds ratio 
greater than 1 would represent differences in the hospital (as the patients are identical). 
The MOR is calculated using the formula: MOR=exp(0.95*se), where se is the standard 
error of the random hospital intercept.15 We also calculated ICC for key performance 
measures by year, and tested for trend across years using inverse variance weighted 
linear regression, to examine whether variation in outcomes has changed across years. 
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All analyses were performed using Stata IC, version 12. Study findings are reported in 
accordance with the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) recommendations.16 No ethics approval was required for this analysis; the 
National Heart Failure Audit was conducted with the approval of the NHS Information 
Centre. 
Results 
In total, 68,772 patients with HFREF were discharged with a primary diagnosis of heart 
failure from 185 hospitals, between 2007 and 2013.  The median (interquartile interval) 
age was 75 (68, 84) and 36.5% were female.  
 
From 2007 to 2013, no significant improvement in rates of prescription of ACE-I or 
referral for specialist follow-up was observed (Table 1). However, rates of prescription of 
beta-blockers increased from 56% to 82% (p trend < 0.001), which drove an increase in 
the composite score from 73% to 84% (p trend <0.001). Risk-adjusted one-year mortality 
decreased from 27% in 2007 to 23% in 2011 (p trend < 0.001), although no appreciable 
change was observed in risk-adjusted 30-day mortality (Table 1).  
 
The composite performance score at the hospital level showed modest variation (median 
79%, range 50% to 97%; Figure 1A and Supp. Figure 1). Amongst the three individual 
components of the composite performance score, prescription of ACE-I /ARB at discharge 
had the highest adherence and lowest variation in its prescription among hospitals 
(median 84%, range 62% to 99%; Figure 1B). The prescription of beta-blockers at 
discharge was lower but with similar variability among hospitals (median 75%, range 
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45% to 96%; Figure 1C); while follow-up with a specialist had the largest variation 
(median 81%; range; 20%, 100%; Figure 1D).  
 
In stratified analyses of the composite performance score, hospitals in the top fifth of 
composite performance score (Q5), compared to those in the bottom fifth (Q1), had a 
higher proportion of tertiary hospitals and consultant cardiologists (Table 2). The 
presence and composition of the multidisciplinary heart failure teams also differed 
between hospital fifth scores, with hospitals in the top fifth being more likely to have a 
multidisciplinary heart failure team. There were no statistically significant differences 
across fifths of hospitals with regard to referral pathways, including referral for heart 
transplantation or for cardiac rehabilitation.  
 
With the composite performance score as a continuous outcome, we performed backward 
stepwise regression and included all hospital characteristics. We found two statistically 
significant predictors of higher adherence to KPMs and retained these in the final model; 
the number of consultant cardiologists working in the hospital and the presence of a 
multidisciplinary heart failure team with a pharmacist (Table 3). However, their absolute 
effect on the composite performance score was small; on average, the presence of a 
multidisciplinary team with a pharmacist was associated with an increase of 3.9% (CI 
1.1%, 6.8%; p=0.003) in performance score. The addition of ten more full-time equivalent 
cardiologists was associated with an increase of 3.5% (CI 1.2%, 5.8%; p=0.007) in 
performance score. 
 
In an unadjusted (null) linear multilevel model, the ICC for the composite performance 
score was 9% (CI 7%, 11%), suggesting that only 9% of the total national variation in 
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adherence to the composite performance score was related to differences amongst 
hospitals (Table 4). Thus, variability within hospitals (related to patient factors, random 
variation, or other known or unknown factors within hospitals) greatly exceeded the 
variability amongst hospitals (due to known or unknown hospital features). When year of 
admission and patient features were added to the model, the ICC decreased from 9% to 
8%, indicating that variation in the type of patient managed by different hospitals and 
year of admission explained only 1% of the total variability amongst hospitals (Table 4).  
Addition of known organisational features reduced this variability by another 1%, 
suggesting that these features had a small absolute and relative influence on the 
variability in the composite performance score (proportion of residual variability 
explained by known organisational features was 12.7%, Table 4). No evidence of change 
in the ICC for any of the five performance measures across years was observed (Supp. 
Table 1) Estimates were similar when a propensity score was adjusted for rather than 
adjusting for covariates (Supp. Table 2). 
 
The variability in prescription of ACE-I/ARB and beta-blockers was concordant with the 
overall composite performance score. Of the total variability in prescription of ACE-I/ARB 
and beta-blockers, only 8% and 7% were attributable to differences amongst hospitals 
(ICC 0.08, CI 0.06, 0.10 and 0.07, CI 0.06, 0.09, respectively). However, hospital-level 
variation in the rate of referral for specialist follow-up was 26%, even after adjustment 
for patient characteristics (ICC 0.26, CI 0.22, 0.31). The median odds ratio for referral for 
specialist follow-up was 2.94 (CI 2.63, 3.33), suggesting that, on average, the odds of a 
patient being referred for specialist follow-up after discharge would differ approximately 
three fold from one randomly selected hospital to another hospital with higher odds 
(Table 4).  
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In our secondary analyses of mortality following discharge, we found that at the hospital 
level, mortality at 30-days ranged from 2.1% to 14.3% and for one year from 10.4% to 
43.6%. In an unadjusted multilevel model, the ICC for death at 30-days and one year after 
discharge were 2% (CI 1%, 3%), and 1% (CI 1%, 2%), respectively, suggesting that only 1 
to 3% of the total national variation in death rates were related to variations in known or 
unknown hospital-level features (Table 4). 
Discussion  
This analysis of the National Heart Failure Audit shows substantial variation in hospital 
adherence to a composite of key performance measures for management of patients 
hospitalized with HFREF. However, only a small fraction of this variation was attributable 
to between-hospital differences in care provision. This overall low hospital-attributable 
variation was mainly driven by high rates of ACE-i/ARB and beta-blocker prescription 
with small degrees of hospital-attributable variations (7% and 6% of the total variability, 
respectively). However, variation in referral for specialist follow-up was substantial and 
26% of it was due to hospital-level features.  
 
Previous studies have reported wide variations in management of patients with heart 
failure across different healthcare systems 4,17,18 and others have shown certain hospital-
level features to be associated with better clinical outcomes.19 The present study goes 
beyond these earlier findings. By quantifying the extent to which variation in KPM can be 
attributed to hospital-level features, this study raises important questions about the 
potential impact of further organisational changes that target individual hospitals. 
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Broadly consistent with previous suggestions, we found several in-hospital organisational 
features to be significantly associated with hospital-level performances. However, we 
further show that the absolute effect of these organisational features on explaining 
variability in adherence to key performance measures, particularly ACE-inhibitor/ARB 
and beta-blocker prescription, is small.  Although the number of consultant cardiologists 
working in the hospital and the presence of a multidisciplinary heart failure team with a 
pharmacist were strongly associated with the hospital performances, they collectively 
accounted for only 1% of the total hospital variation. 
 
These findings indicate that the majority of remaining variability in prescription of ACE-
i/ARB and beta-blocker is randomly distributed among hospital providers and is not 
determined by differences in organisational features among hospitals. Whilst further 
investment into costly organisational changes for management of HFREF in hospitals in 
England and Wales may still be useful for changing other important healthcare outcomes 
across all hospitals, our study shows that such investments cannot be expected to lead to 
large reductions in variability in hospital adherence to these performance measures. Even 
if we assume that the observed associations between hospital preferences (e.g., presence 
of multi-disciplinary teams) and hospital performances (e.g., prescription rates for beta-
blocker) are causally related, additional changes to such hospital preferences for in-
hospital care would only be expected to reduce the absolute between-hospital variability 
in the ACE-i/ARB or beta-blocker prescription by less than 5%. Whether such modest 
reductions in the process outcomes are worthwhile require formal health economic 
evaluation before any recommendations can be made about additional changes to service 
delivery in the UK hospitals.20 These results also suggest that research should be 
undertaken to characterize hospital-level variation in key performance measures for 
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heart failure in other countries. The modest effects of quality improvement programs on 
heart failure care in the United States 21may be due to limited variation in key 
performance measures, as observed in this analysis. 
 
 
The only key performance measure for which we observed large variation amongst 
hospitals was referral to specialist follow-up (either to a heart failure nurse or 
cardiologist). After case-mix adjustment, there was still an almost three times difference 
in the odds of a patient being referred for specialist follow-up between two randomly 
selected hospitals. Twenty percent of this variation was explained by known differences 
in hospital practices and overall the average adherence to specialist follow-up after 
discharge did not change from 2007 to 2013. If specialist follow-up influences outcomes 
in heart failure, as has been suggested by prior studies, such high levels of variation may 
partially explain differences in risk of death among hospitals. There are several potential 
explanations for this observation. First, it is likely that adherence to this key performance 
measure is more difficult and resource-intensive than making changes to prescription of 
evidence-based therapies. Second, it may be that there is less professional agreement 
about this performance measure because the level of evidence for it is less strong than 
pharmacological interventions.22 Randomised evidence on the effect of early specialist 
follow-up after discharge is limited 23,24 and findings from non-randomised comparisons 
have been inconsistent.25–27  
 
This study has several strengths. First, recommended performance measures were 
selected as the primary outcome,3,10 as opposed to clinical endpoints, thus avoiding the 
risk of uncontrolled residual confounding when mortality or hospitalisation are 
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chosen.12,28 Second, we separated the evaluation of in-hospital performance from post-
discharge performance to take account of differences in recommended care during these 
very different phases of care. Third, we linked a survey of organisational features to 
hospital processes and used multi-level analysis to quantify the impact of such features on 
quality of care, thus extending previous studies which have been criticized for largely 
investigating associations between structural hospital features, such as number of beds or 
volume of patients, which are not amenable to change.29 Finally, we included a large 
number of confirmed cases of HFREF with linked databases and hence were able to 
investigate the quality of care in a more accurate and detailed manner than previous 
reports.  
 
However, this study also has several potential limitations. First, many other aspects of 
heart failure care, in addition to prescription of ACE-I/ARBs, beta-blockers and specialist 
follow-up, may influence outcomes after hospitalization for HFREF. However, other 
evidence-based interventions, such as mineralocorticoid receptor antagonists or cardiac 
resynchronization therapy are currently not recommended as the minimum performance 
measures for in-hospital care. These results therefore suggest that future research should 
examine whether these evidence-based interventions would be better suited as 
performance measures, considering the relatively high prescription rates and modest 
hospital level variation of ACE-inhibitor/ARBs and beta-blockers observed. Second, we 
lacked information on the dosage of prescribed medications, which are an important 
determinant of outcomes in heart failure and may exhibit greater variation among 
hospitals than prescription rates.30 Third, the small between-hospital variation observed 
in this study may not be generalisable to health systems which are more diverse than the 
NHS in terms of organisation and delivery of care for patients with acute heart failure4. 
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Fourth, although hospitals were asked to provide information from the first unselected 10 
or 20 patients admitted to their hospital each month, we cannot entirely rule out that 
patients included differ in some respects from those that have not been included in the 
reports. Finally, we focused our analysis on quantification of differences in natural 
variation among hospitals in order to estimate the impact of variation in hospital 
preferences on key performance measures. In theory, it is, however, possible that 
interventions that equally target all hospitals could lead to an average increase (or 
decrease) in hospital performances across all hospitals even when there is not much 
between-hospital variability but average performance is uniformly low (or high).  
 
In conclusion, we observed an improvement in hospital performances for management of 
patients with HFREF over time. Although substantial variation in adherence to key 
performance measures was observed, only a small proportion of this could be attributed 
to between-hospital differences. These results suggest that further organisational changes 
that would specifically target low performing hospitals will have limited impact on 
reducing variation in prescription rates of ACE-inhibitors/ARBs and beta-blockers for 
patients with HFREF in the UK. Future hospital-level organisational changes should 
consider focusing on improving rates of referral to specialist follow-up after discharge, for 
which there is substantial variation. Future research should also examine whether other 
evidence-based interventions, such as prescription of mineralocorticoid receptor 
antagonists or cardiac resynchronization therapy or prescription of recommended 
dosages of medications, should be used as performance measures for in-hospital care. 
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Figure Legend 
Figure 1. Variation in (A) the composite performance score (B) prescription of ACE-
inhibitors/ARBs (C) prescription of beta-blockers and (D) referral for specialist follow up 
performance measures among 185 hospitals.  
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Tables 
 
Table 1. Temporal trends in hospital adherence to key performance measures and risk of death after discharge in 185 hospitals in 
England and Wales 
 
 
        Year         
  
2007 
(n=320) 
2008 
(n=3380) 
2009 
(n=8622) 
2010 
(n=14656) 
2011 
(n=17466) 
2012 
(n=19071) 
2013 
(n=5257) 
Test for 
trend 
Composite performance score 73% (CI 70%, 76%) 77% (CI 76%, 78%) 78% (CI 78%, 79%) 79.0% (CI 79%, 80%) 81% (CI 80%, 81%) 83% (CI 82%, 83%) 84% (CI 83%, 85%) p<0.001 
ACE-I/ARB 79% (CI 69%, 90%) 83% (CI 80%, 87%) 84% (CI 82%, 86%) 83% (CI 82%, 85%) 83% (CI 82%, 85%) 84% (CI 83%, 86%) 84% (CI 82%, 86%) p=0.556 
Beta-blockers 56% (CI 47%, 67%) 63% (CI 60%, 66%) 67% (CI 65%, 69%) 70% (CI 68%, 72%) 75% (CI 73%, 77%) 80% (CI 78%, 81%) 82% (CI 79%, 85%) p<0.001 
Specialist follow-up 79% (CI 68%, 92%) 78% (CI 75%, 82%) 79% (CI 76%, 82%) 79% (CI 77%, 82%) 79% (CI 77%, 82%) 80% (CI 78%, 83%) 81% (CI 78%, 84%) p=0.081 
         
Risk-adjusted 30-day mortality 3.5% (CI 2.0%, 6.0%) 5.4% (CI 4.7%, 6.3%) 5.4% (CI 4.9%, 5.9%) 4.8% (CI 4.5%, 5.2%) 5% (CI 4.7%, 5.4%) 5.1% (CI 4.7%, 5.4%) 5.1% (CI 4.5%, 5.7%) p=0.663 
Risk-adjusted one-year mortality 27% (CI 22%, 33%) 28% (CI 26%, 30%) 26% (CI 25%, 27%) 25% (CI 24%, 26%) 23% (CI 22%, 24%) - - p<0.001 
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Table 2. Key performance measures and hospital characteristics across fifths of 
composite performance score 
 Hospital-Level Composite Performance Score  (n, range) 
 
 
Q1 (n=37, 
49.8% -
71.6%) 
Q2 (n=37, 
71.7% - 
77.3%) 
Q3  
(n=37, 
77.4%, 
81.6%) 
Q4 (n=37, 
81.8%, 
86.6%) 
Q5 (n=37, 
86.7%, 
97.0%) 
Test for 
Trend 
Composite Performance 
Score 
66.6% 74.5% 79.3% 84.2% 89.3% p<0.001 
ACE-I/ARB 76.2% 80.3% 83.7% 86.4% 90.8% p<0.001 
Beta-blockers 63.4% 69.0% 75.7% 77.2% 84.5% p<0.001 
Specialist Follow-up 60.2% 74.2% 78.5% 89.1% 92.7% p<0.001 
Hospital Characteristics       
Tertiary Hospital 9.2% 12.4% 5.4% 22.7% 34.1% p=0.002 
General Hospital 88.1% 87.6% 91.9% 75.1% 65.4% p=0.004 
Other Hospital 2.7% 0% 2.7% 2.2% 0.5% p=0.75 
Heart Failure Specialist 
Nurse FTEs, No. 
3.4 4.4 4.5 4.7 4.3 p=0.18 
Consultant Cardiologist 
FTEs, No. 
4.1 4.6 4.7 5.7 8.5 p<0.001 
Consultant HF Specialist 
Cardiologist 
89.2% 77.8% 84.9% 88.1% 95.1% p=0.21 
Other HF Specialist 
Consultant 
27.6% 16.8% 18.4% 26.5% 35.1% p=0.28 
Multidisciplinary Team 
(% of hospitals) 
69.7% 71.9% 78.9% 80.5% 96.2% p=0.003 
With a Consultant 
Cardiologist 
69.7% 71.9% 78.9% 80.5% 93.5% p=0.008 
With a Heart Failure Nurse 69.7% 71.9% 78.9% 80.5% 96.2% p=0.003 
With another Consultant 21.6% 24.3% 16.8% 25.4% 44.3% p=0.045 
With a District Nurse 10.8% 10.8% 3.8% 13.0% 7.6% p=0.78 
With a Pharmacist 8.1% 14.1% 19.5% 33.5% 33.0% p=0.001 
With a Dietician 5.4% 8.1% 6.5% 11.9% 16.8% p=0.09 
With a Physiotherapist 21.1% 21.6% 12.4% 19.5% 36.2% p=0.20 
With a Psychologist 13.5% 4.9% 11.4% 18.9% 35.1% p=0.003 
With a Primary Provider 14.1% 8.6% 23.8% 23.8% 32.4% p=0.01 
With a Social Worker 0% 0% 2.7% 5.4% 8.1% p=0.02 
Diagnostic Capabilities        
ECG 100% 100% 100% 100% 100% p=1.0 
BNP 54.6% 68.6% 62.7% 68.6% 75.1% p=0.10 
Exercise Testing 97.3% 100% 100% 97.3% 94.6% p=0.29 
Echocardiography 97.3% 100% 100% 100% 100% p=0.16 
Coronary Angiography 63.2% 82.2% 84.3% 82.7% 84.9% p=0.04 
Cardiac MRI 24.9% 21.1% 48.6% 43.2% 51.4% p=0.003 
Referral Pathways          
Internal Defibrillator 98.4% 98.9% 100% 100% 100% p=0.30 
Cardiac Resynchronization 
Therapy 
95.7% 96.2% 100% 100% 97.3% p=0.37 
Transplantation 87.0% 88.6% 83.8% 93.5% 90.3% p=0.50 
Left Ventricular Assistive 
Device 
84.3% 80% 67.0% 78.4% 76.8% p=0.46 
Palliative Care 100% 100% 93.5% 98.4% 100% p=0.81 
Cardiac Rehabilitation 74.6% 81.6% 74.6% 80% 89.2% p=0.19 
Outpatient Services       
HF Clinic 86.4% 80% 79.5% 87.6% 96.2% p=0.14 
Cardiologist 61.1% 61.6% 60% 75.1% 82.7% p=0.02 
Heart Failure Specialist 
Nurse 
76.2% 67.6% 58.9% 84.9% 93.5% p=0.02 
Physician with HF Interest 7.0% 12.4% 11.9% 14.6% 16.2% p=0.24 
Primary Care 6.5% 1.6% 8.1% 4.9% 5.9% p=0.86 
Geriatrician 8.1% 2.7% 0% 5.4% 10.8% p=0.49 
Pharmacist 2.7% 3.8% 10.8% 9.7% 8.1% p=0.22 
Telemonitoring 32.4% 25.9% 45.9% 35.7% 51.9% p=0.057 
Cardiac Surgery 86.5% 95.1% 88.6% 91.9% 100% p=0.09 
Abbreviations: ACE-I/ARB: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; FTE: Full time equivalents; ECG: 
electrocardiography; BNP: B-type natriuretic peptide; Cardiac MRI: Cardiac magnetic resonance imaging 
Note that multiple imputation results in different hospitals being assigned to different fifths in the five imputations. As a result, some 
percentages are not fractions of 37.  
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Table 3. Hospital characteristics associated with better composite performance score 
after stepwise regression.1 
 
 
% Change in Composite Score 
(95% CI) p-value 
Number of FTEs of Consultant Cardiologists 
(units of 10 cardiologists) 2 3.5% (CI 1.2%, 5.8%) p=0.003 
 
 Presence of a Multidisciplinary Heart Failure 
Team with a Pharmacist 3.9% (CI 1.1%, 6.8%) p=0.007 
 
1Mutually adjusted for number of FTEs of consultants cardiologist and presence of a multidisciplinary heart failure team 
with a pharmacist, after stepwise elimination with a p-value for elimination of 0.01. 
2 Full time equivalents 
 
Table 4. Inter-hospital variability in adherence to individual key performance measures, 
their composite performance score and mortality at 30 days and at one year after 
discharge 
 
 
Null Model Adjusted for Patient Characteristics + 
Year 
Adjusted for Hospital  + Patient 
Characteristics + Year 
Key Performance 
Measure 
ICC1 
Median Odds 
Ratio 
ICC 
Median Odds 
Ratio 
Proportion 
of Variance 
Explained4 
ICC 
Median 
Odds Ratio 
Proportion 
of Variance 
Explained5 
         
Composite 
Performance 
Score2 
0.09  
(CI 0.07, 0.11) 
- 
0.08 
 (CI 0.07, 
0.10) 
- 12.1% 
0.07  
(CI 0.06, 
0.09) - 12.7% 
ACE-I/ARB3 
0.08  
(CI 0.06, 0.10) 
1.70  
(CI 1.60, 1.82) 
0.07  
(CI 0.06, 
0.09) 
1.67  
(CI 1.57, 
1.79) 
5.2% 
0.07  
(CI 0.06, 
0.09) 
1.66  
(CI 1.56, 
1.77) 3.3% 
         
Beta-blocker 
0.07  
(CI 0.06, 0.09) 
1.65 (CI 1.56, 
1.76) 
0.06  
(CI 0.05, 
0.08) 
1.59  
(CI 1.51, 
1.68) 
13.7% 
0.06 
 (CI 0.04, 
0.07) 
1.56  
(CI 1.48, 
1.65) 7.6% 
         
Specialist 
Follow-up 
0.27  
(CI 0.23, 0.31) 
2.99  
(CI 2.67, 3.40) 
0.26  
(CI 0.22, 
0.31) 
2.94  
(CI 2.63, 
3.33) 
2.3% 
0.21  
(CI 0.18, 
0.25) 
2.55  
(CI 2.31, 
2.85) 19.4% 
30-day mortality 
0.02  
(CI0.01, 0.03) 
1.29  
(CI 1.23, 1.36) 
0.02  
(CI 0.01, 
0.02) 
1.25  
(CI 1.20, 
1.32) 
20.0% 
0.01  
(CI 0.01, 
0.02) 
1.24  
(CI 1.18, 
1.30) 12.2% 
1-year mortality 
0.01  
(CI 0.01, 0.02) 
1.25  
(CI 1.21, 1.29) 
0.01  
(CI 0.01, 
0.01) 
1.18  
(CI 1.15, 
1.22) 
41.3% 
0.01  
(CI 0.01, 
0.01) 
1.17  
(CI 1.14, 
1.21) 10.8% 
 
1ICC denotes intra-class correlation coefficient 
2As a continuous variable, a median odds ratio is not calculable. 
3Provision of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 
4Relative to the null model. 
5Relative to the model adjusted for patient characteristics 
 
 
 
